trending Market Intelligence /marketintelligence/en/news-insights/trending/YQW67gUyQ6Bs7-iZwkwFyg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Biosimilar maker Mabpharm applies for Hong Kong IPO

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Biosimilar maker Mabpharm applies for Hong Kong IPO

Mabpharm Ltd, a pre-revenue company developing biosimilars of therapies for cancers and autoimmune diseases, applied to go public in Hong Kong.

Biosimilars are intended to be lower-cost versions of biologic therapies.

Goa, India-based Mabpharm's CMAB007, a copycat version of Roche Holding AG's asthma drug Xolair; CMAB009, a biosimilar of Eli Lilly and Co.'s head and neck cancer drug Erbitux and CMAB008, a copy of Johnson & Johnson's inflammatory disease drug Remicade are all being evaluated in clinical trials.

The company's CMAB809 and CMAB819, biosimilars of AbbVie Inc.'s top-selling inflammatory disease drug Humira and Bristol-Myers Squibb Co.'s cancer immunotherapy Opdivo, respectively, have also been approved for clinical trials.

China International Capital Corp. Hong Kong Securities Ltd. is the sole sponsor for the IPO.

Hong Kong has wooed biotechnology companies to list in the city after it tweaked its listing rules in April 2018 to allow pre-revenue companies to go public on its exchange. China is also planning a similar move to attract pre-revenue biotechs.